Compare AUTL & IRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUTL | IRMD |
|---|---|---|
| Founded | 2014 | 1992 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.8M | 910.4M |
| IPO Year | 2018 | 2014 |
| Metric | AUTL | IRMD |
|---|---|---|
| Price | $1.67 | $97.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $8.33 | ★ $72.00 |
| AVG Volume (30 Days) | ★ 2.5M | 80.6K |
| Earning Date | 11-12-2025 | 02-12-2026 |
| Dividend Yield | N/A | ★ 0.70% |
| EPS Growth | N/A | ★ 13.00 |
| EPS | N/A | ★ 1.65 |
| Revenue | $51,128,000.00 | ★ $80,511,268.00 |
| Revenue This Year | $658.11 | $15.17 |
| Revenue Next Year | $91.34 | $10.15 |
| P/E Ratio | ★ N/A | $58.83 |
| Revenue Growth | ★ 406.67 | 12.91 |
| 52 Week Low | $1.11 | $47.48 |
| 52 Week High | $2.80 | $98.44 |
| Indicator | AUTL | IRMD |
|---|---|---|
| Relative Strength Index (RSI) | 59.67 | 65.84 |
| Support Level | $1.56 | $90.92 |
| Resistance Level | $1.79 | $98.24 |
| Average True Range (ATR) | 0.09 | 2.55 |
| MACD | 0.01 | -0.43 |
| Stochastic Oscillator | 66.67 | 81.65 |
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.